Transcept Pharmaceuticals Inc (TSPT)

[bigboard]

SHORT this PIG all the way to 2.0 - do not fear
Biotech turds like this get pumped and dumped like clockword

[otcmoneydoubler]

hey Surf.can u explain how TSPT special cash dividend works?

[surf1944]

Buying into several small cap biotechs like TSPT the past week for move into the new year:

http://stockcharts.com/h-sc/ui?s=tspt&p=D&yr=0&mn=13&dy=0&id=p38090673899

[stocktrademan]

$TSPT recent news/filings

bullish 10-15% in a week or more longer term

## source: finance.yahoo.com

Thu, 03 Jul 2014 18:35:33 GMT ~ TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure


read full: http://biz.yahoo.com/e/140703/tspt8-k.html
*********************************************************

Wed, 02 Jul 2014 05:00:23 GMT ~ Paratek Pharmaceuticals signs merger agreement with NASDAQ-listed Transcept Pharmaceuticals

[at noodls] - NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA Media Release Zug, 2 July 2014 Paratek Pharmaceuticals signs merger agreement with NASDAQ-listed Transcept Pharmaceuticals Paratek Pharmaceuticals, ...

read full: http://www.noodls.com/view/A7D6234787265D35C0D83BC41DB551F05BC16A65
*********************************************************

Tue, 01 Jul 2014 20:12:14 GMT ~ TRANSCEPT PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/140701/tspt8-k.html
*********************************************************

Tue, 01 Jul 2014 10:30:00 GMT ~ Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO

[GlobeNewswire] - BOSTON -- Paratek Pharmaceuticals, Inc., today announced that Michael F. Bigham, Partner at Abingworth LLP, has been appointed as Chairman of the Board of Directors and Chief Executive Officer. In addition, ...

read full: http://finance.yahoo.com/news/paratek-appoints-michael-bigham-chairman-103000860.html
*********************************************************

Tue, 01 Jul 2014 10:15:00 GMT ~ Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement

[PR Newswire] - BOSTON, Mass., and POINT RICHMOND, Calif., July 1, 2014 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (TSPT) and Paratek Pharmaceuticals, Inc., a privately-held biopharmaceutical company, announced today that they have entered into a definitive merger agreement under which the stockholders of Paratek will become the majority owners of Transcept and the operations of Transcept and Paratek will be combined. As part of the proposed transaction, new investors (including The Baupost Group, Abingworth LLP, and other institutional investors); Glenn Oclassen, Chief Executive Officer and Chairman of the Transcept Board, commented: "Following Transcept's recent June 3, 2014 special cash dividend of approximately $25.4 million, this transaction with Paratek reflects the continued commitment of Transcept's Board of Directors and management team to deliver value to Transcept's stockholders. Under the proposed transaction, Transcept's stockholders will maintain a meaningful equity ownership stake in Transcept, which will refocus its operations as a late-stage therapeutics company with product candidates we believe possess significant commercial potential. The transaction also provides for our stockholders an additional special cash dividend and the opportunity to realize any upside potential from our INTERMEZZO and TO-2070 assets."

read full: http://finance.yahoo.com/news/transcept-pharmaceuticals-paratek-pharmaceuticals-sign-101500418.html
*********************************************************


$TSPT charts

basic chart ## source: stockcharts.com




big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$TSPT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/TSPT/company-info
Ticker: $TSPT
OTC Market Place: Not Available
CIK code: 0001178711
Company name: Transcept Pharmaceuticals, Inc.
Incorporated In:


$TSPT share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$TSPT extra dd links

Company name: Transcept Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=TSPT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=TSPT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=TSPT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/news - http://finance.yahoo.com/q/h?s=TSPT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/TSPT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=TSPT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/TSPT
DTCC (dtcc.com): http://search2.dtcc.com/?q=Transcept+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Transcept+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Transcept+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/TSPT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001178711&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=TSPT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=TSPT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=TSPT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=TSPT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=TSPT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=TSPT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=TSPT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/TSPT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=TSPT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/TSPT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=TSPT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/TSPT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/TSPT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/TSPT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/TSPT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/TSPT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=TSPT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=TSPT



$TSPT DD Notes ~ http://www.ddnotesmaker.com/TSPT
a11k

[surf1944]

2:18AM Transcept Pharma provides update on key initiatives to increase shareholder value (TSPT) 3.52 : Co provides an update to the key initiatives being pursued to increase stockholder value.
The Transcept Board and management team have taken, or are undertaking, the following steps:


In November 2013 co announced the reduction of 6 employees, or ~43% of workforce. In connection with this restructuring, Thomas Soloway, Executive Vice President and Chief Operating Officer, notified the Company that he would resign effective December 31, 2013. With these combined changes, co expects that headcount will be reduced by ~50% and our annual payroll and benefits expense will be reduced by ~$1.23 mln, or 37% of the annual Transcept payroll.
Effective December 31, 2013, Glenn Oclassen, President and Chief Executive Officer, will assume the role of Chairman of the Board and Chief Executive Officer. Concurrently, Kirk Raab, the Company's current Chairman of the Board, will move to the position of Lead Independent Director. Christopher Ehrlich, a longstanding member of the Transcept Board of Directors, will resign from the Board effective December 31, 2013. This restructuring is expected save the Company ~$180,000 on an annualized basis, or 36% of its board governance costs.
Co is continuing our work with Leerink Swann, co's previously announced financial and strategic advisor, to explore a range of alternatives to enhance stockholder value, including a sale of the Company, a business combination, partnership opportunities and distribution of all or a significant amount of cash to stockholders. In particular, co is actively seeking a merger partner and intend to continue this effort into the first quarter of 2014, while continuing to remain open to all stockholder value enhancing opportunities. Co is evaluating a range of alternatives, some of which may result in a transaction with a partial distribution of cash to stockholders concurrent with the transaction. If we cannot identify a transaction in the first quarter 2014, co intends to proceed with a liquidation of the Company.
Co will continue to develop TO-2070, our DHE product candidate for the treatment of acute migraine, through the completion of preclinical safety studies. Co believesthat the continued development of TO-2070 through a successful completion of pre-clinical safety studies will add value to the asset that may be recognized in a potential transaction. Given the timing of the strategic process described above, co does not intend to initiate a Phase 1 human pharmacokinetic study.
Co continues to work with Purdue Pharma, our U.S. marketing partner for Intermezzo, to develop and implement strategies to maximize the value of Intermezzo.

[surf1944]

7:31AM Transcept Pharma sets special stockholder meeting for Dec 19, 2013; co continues to explore strategic alternatives (TSPT) 3.37 : Co announced that it will hold a special meeting of stockholders on Dec 19, 2013. The meeting arises from a request from a stockholder group that includes: Roumell Asset Management, Retrophin and SC Fundamental Value Fund. This stockholder group is seeking to remove four of the seven current members of the Transcept Board of Directors and to vote on a non-binding resolution calling on the Board to eliminate the Tax Benefit Preservation Plan that the Transcept Board unanimously adopted on Sep 13, 2013 to protect the value of Transcept's cumulative net operating loss carry forwards ("NOLs"). As previously disclosed, the NOLs may have meaningful value to all Transcept stockholders in the future, either to shelter future income or in connection with a strategic transaction.

The co believes that the special meeting request is deficient in a number of respects. However, rather than forcing the stockholder group to revise the request, the Board will call the special meeting to allow all stockholders to make a fully informed decision on these matters. The Transcept Board has established a Nov 5, 2013 record date for stockholders entitled to vote at the special meeting. In contrast to the Board's ongoing exploration of strategic alternatives and other initiatives to create value for all stockholders, the co believes that the objective of this stockholder group is to seize control of Transcept without paying full and fair value to all stockholders.

[surf1944]

8:40AM Transcept Pharma announced that it had received a communication from Retrophin stating that it owns 4.9% of the outstanding common stock of TSPT and seeking permission from the Board of Directors of Transcept to increase its ownership stake up to 15% (TSPT) 3.27 : Co announced that it had received a communication from Retrophin stating that it owns 4.9% of the outstanding common stock of Transcept and seeking permission from the Board of Directors of Transcept to increase its ownership stake up to 15% of the outstanding common stock of Transcept. After consultation with its financial and legal advisors, and after evaluating the Retrophin request in the context of the tax benefit preservation plan adopted on September 13, 2013, the Board of Directors of Transcept unanimously determined not to accede to this request.

During its deliberations, the Board of Directors of Transcept determined that granting the Retrophin request could jeopardize the value of the approximately $78 million in net operating loss carry forwards of Transcept. The tax benefit preservation plan was unanimously adopted by the Board to protect this asset for the benefit of all Transcept stockholders.

[Penny Roger$]

$TSPT > Technical bounce watch this week >

TSPT has hit the ol' scanner and has a fair chance of a bounce at these levels. Stocks that have declined this badly almost always retrace higher, bounce or dip some and come right back to this point before a further decline.
Contacting me with the fundamentals about the company does not change my criteria for scanning stocks.

If you just started shorting this stock, it might be a bad idea as this is totally oversold!



All of the "FASTLANE's BOMB's AWAY! SCANS" are of my own opinion and not to be used as investment advice.




$TSPT - Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=TSPT
$TSPT - Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=TSPT
$TSPT - Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=TSPT
$TSPT - Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=TSPT
$TSPT - Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=TSPT
$TSPT - Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=TSPT&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260




Regular Candlestick Chart: http://stockcharts.com/h-sc/ui?s=TSPT&p=D&b=3&g=0&id=p04384940601




Regular Candlestick Chart: http://stockcharts.com/h-sc/ui?s=TSPT&p=W&b=3&g=0&id=p04384940601







PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/TSPT


OTC Markets Company Info ~ http://www.otcmarkets.com/stock/TSPT/company-info
$TSPT - OTC Markets Charts ~ http://www.otcmarkets.com/stock/TSPT/chart
$TSPT - OTC Markets Quote ~ http://www.otcmarkets.com/stock/TSPT/quote
$TSPT - OTC Markets News ~ http://www.otcmarkets.com/stock/TSPT/news
$TSPT - OTC Markets Financials ~ http://www.otcmarkets.com/stock/TSPT/financials
$TSPT - OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/TSPT/short-sales
$TSPT - OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/TSPT/insider-transactions
$TSPT - OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/TSPT/research


Google Finance Summary ~ http://www.google.com/finance?q=TSPT
$TSPT - $TSPT - Google Finance News ~ http://www.google.com/finance/company_news?q=TSPT
$TSPT - Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=TSPT
$TSPT - Google Finance Financials ~ http://www.google.com/finance?q=TSPT&fstype=ii#
$TSPT - Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=TSPT
$TSPT - Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=TSPT&histperiod=weekly#


Y! < Company >
$TSPT - Y! Profile ~ http://finance.yahoo.com/q/pr?s=TSPT+Profile
$TSPT - Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=TSPT+Key+Statistics
$TSPT - Y! Headlines ~ http://finance.yahoo.com/q/h?s=TSPT+Headlines
$TSPT - Y! Summary ~ http://finance.yahoo.com/q?s=TSPT
$TSPT - Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=TSPT+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=TSPT+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/TSPT
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/TSPT
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=TSPT+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=TSPT+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=TSPT+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=TSPT+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=TSPT+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=TSPT+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=TSPT+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=TSPT+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=TSPT+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=TSPT+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=TSPT+Cash+Flow&annual


FINVIZ ~ http://finviz.com/quote.ashx?t=TSPT&ty=c&ta=0&p=d


CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=TSPT&exchange=US




$TSPT - Barchart Quote ~ http://barchart.com/quotes/stocks/TSPT?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/TSPT
Barchart Options Quotes ~ http://barchart.com/options/stocks/TSPT
Barchart Technical Chart ~ http://barchart.com/charts/stocks/TSPT&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/TSPT&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/TSPT
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=TSPT
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/TSPT
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/TSPT
Barchart News Headlines ~ http://barchart.com/news/stocks/TSPT
Barchart Profile ~ http://barchart.com/profile//TSPT
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=TSPT&view=key_statistics


OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=TSPT&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=TSPT&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=TSPT&MarketTicker=NYSE&Typ=S


Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/TSPT/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/TSPT/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/TSPT/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/TSPT/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/TSPT
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/TSPT/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/TSPT/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/TSPT/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/TSPT/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/TSPT/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/TSPT/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=TSPT&sid=1795093&framed=False


The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=TSPT


Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=TSPT


StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=TSPT&num1=567&cobrand=&mode=stock


StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=TSPT
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=TSPT


AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=TSPT&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8


Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=TSPT.PK&WTmodLOC=C4-Officers-5


StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=TSPT®ion=U


Search NASDAQ ~ http://www.nasdaq.com/symbol/TSPT
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/TSPT/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/TSPT/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/TSPT/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=TSPT&selected=TSPT
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=TSPT&selected=TSPT
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/TSPT/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/TSPT/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/TSPT/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/TSPT/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/TSPT/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/TSPT/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/TSPT/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/TSPT/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/TSPT/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/TSPT/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/TSPT/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/TSPT/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/TSPT/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/TSPT/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=TSPT&selected=TSPT
NASDAQ Financials ~ http://www.nasdaq.com/symbol/TSPT/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/TSPT/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/TSPT/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/TSPT/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/TSPT/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/TSPT/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/TSPT/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/TSPT/insider-trades/sells


The Motley Fool ~ http://caps.fool.com/Ticker/TSPT.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/TSPT/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/TSPT/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/TSPT/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/TSPT/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/TSPT/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/TSPT/Statements.aspx?source=icasittab0000009


MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=TSPT


YCharts ~ http://ycharts.com/companies/TSPT
YCharts Performance ~ http://ycharts.com/companies/TSPT/performance
YCharts Dashboard ~ http://ycharts.com/companies/TSPT/dashboard


InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=TSPT&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=TSPT&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=TSPT&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=TSPT


Zacks Quote ~ http://www.zacks.com/stock/quote/TSPT
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=TSPT
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=TSPT


Knobias ~ http://knobias.10kwizard.com/files.php?sym=TSPT


StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=TSPT


Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/TSPT/HOT_TOPIC.html


Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=TSPT&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=TSPT®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=TSPT®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=TSPT®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=TSPT®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=TSPT®ion=USA&culture=en-us


CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=TSPT


TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=TSPT


OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=TSPT&searcharea=e&image1.x=0&image1.y=0


Insidercow ~ http://www.insidercow.com/history/company.jsp?company=TSPT&B1=Search%21


Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=TSPT
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=TSPT&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=TSPT&start=1&max=10&searchResults=web&tag=web&sort=null


YouTube Symbol Search ~ http://www.youtube.com/results?search_query=TSPT


Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=TSPT


Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=TSPT


Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=TSPT

Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=TSPT
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=TSPT

Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=TSPT

Investorpoint ~ http://www.investorpoint.com/ enter "TSPT" and click search.

Hotstocked ~ http://www.hotstocked.com/ enter "TSPT" and click search.

Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=TSPT

Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=TSPT

DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=TSPT

SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=TSPT

OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=TSPT

Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "TSPT" and click search.

http://www.coordinatedlegal.com/SecretaryOfState.html

http://regsho.finra.org/regsho-Index.html

http://www.shortsqueeze.com/?symbol=TSPT&submit=Short+Quote%99

[the_breeze]

Showing some small volume growth here...any thoughts ??

[surf1944]

1:38AM Transcept Pharma comments on new FDA Dosage reduction requirements for Zolpidem based prescription sleep aids administered at bedtime (TSPT) 5.76 : The FDA is requiring that the manufacturers of certain zolpidem based prescription sleep aids such as Ambien and Ambien CR, and generic versions of these products, reduce the recommended dose. FDA has informed the manufacturers of these products that the recommended dose of zolpidem at bedtime for women should be lowered from 10 mg to 5 mg for immediate-release products such as Ambien, and from 12.5 mg to 6.25 mg for extended-release products such as Ambien CR. FDA also informed the manufacturers that, for men, the labeling should recommend that health care professionals consider prescribing the lower doses 5 mg for immediate-release products and 6.25 mg for extended-release products.

The FDA announcement further states, "The recommended doses of Intermezzo, a lower dose zolpidem product approved for middle-of-the-night awakenings, are not changing. At the time of Intermezzo's approval in November 2011, the label already recommended a lower dosage for women than for men." Co states: "We are pleased that this action by FDA confirms the recommended dose of Intermezzo at 3.5 mg in men and 1.75 mg in women for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep, so long as they have at least 4 hours of remaining bedtime."

[mlkrborn]

Transcept Pharmaceuticals announces that a Phase 2 clinical trial of TO-2061 as adjunctive therapy for obsessive compulsive disorder did not meet primary endpoint (TSPT) 5.16 : Co announced initial top-line results from its Phase 2 clinical trial evaluating the efficacy and safety of TO-2061 (ondansetron oral tablets 0.5 mg and 0.75 mg) in patients with obsessive compulsive disorder (OCD) who had not adequately responded to treatment with approved first-line therapies.

The data from the trial showed that TO-2061 did not meet the primary efficacy endpoint to demonstrate an improvement in OCD symptoms versus placebo. Transcept expects to complete the remaining protocol-specified analyses in early 2013 and will make a determination on any future development of TO-2061 after further review of the data.

"It is disappointing that the Phase 2 trial of TO-2061 did not meet its primary endpoint, in particular for those patients suffering from treatment resistant OCD," said Glenn Oclassen, President and Chief Executive Officer of Transcept. "Once we have reviewed the full data set, we will determine next steps, if any, in the clinical development program for TO-2061 for the adjunctive treatment of OCD."

... stock is halted.

[surf1944]

Biotech stocks are starting the EOY up move early this year, TSPT & most others are strong holds into Jan 2013..........

[surf1944]

8:23AM On The Wires (WIRES) :Transcept Pharmaceuticals (TSPT) has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder who have not adequately responded to first-line treatment with an approved OCD medication. The co plans to announce top-line results of this study in 1Q2013.

[surf1944]

Transcept Pharmaceuticals Announces Listing of New U.S. Patent for Intermezzo in FDA's Orange Book
PR NewswirePress Release: Transcept Pharmaceuticals, Inc. – Tue, Aug 21, 2012 4:40 PM EDT

POINT RICHMOND, Calif., Aug. 21, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (TSPT) today announced that the U.S. Food and Drug Administration has listed U.S. Patent No. 8,242,131 (the '131 patent) in its Approved Drug Products with Therapeutic Equivalence Evaluations, or "Orange Book." This patent, which was issued by the United States Patent and Trademark Office (USPTO) on August 14, 2012, includes claims directed to methods of treating middle-of-the-night insomnia with low doses of zolpidem. The '131 patent will expire no sooner than 2029.

As part of the collaboration agreement between Purdue Pharmaceutical Products L.P. (Purdue) and Transcept, Transcept is eligible to receive a $10 million milestone payment from Purdue in connection with the '131 patent being listed in the Orange Book. Pursuant to this agreement, Transcept is also eligible to receive up to an additional $70 million in milestone payments related to the achievement of certain U.S. net sales targets of Intermezzo, as well as a royalty on U.S. net sales of Intermezzo that ranges from the mid-teens to the mid-20% level.

This patent adds to the Intermezzo intellectual property portfolio, which includes two previously issued U.S. patents that are currently listed in the Orange Book. In addition, the USPTO issued a Notice of Allowance on July 18, 2012, for an Intermezzo patent application directed to compositions for treating middle-of-the-night insomnia. Intermezzo was also granted three years of Hatch-Waxman regulatory exclusivity by the FDA.

[mlkrborn]

Transcept Pharma announces listing of new U.S. patent for Intermezzo in FDA's Orange Book (TSPT) 5.65 +0.31 : Co announced that the FDA has listed U.S. Patent No. 8,242,131 (the '131 patent) in its Approved Drug Products with Therapeutic Equivalence Evaluations, or "Orange Book." This patent, which was issued by the United States Patent and Trademark Office (USPTO) on August 14, 2012, includes claims directed to methods of treating middle-of-the-night insomnia with low doses of zolpidem. The '131 patent will expire no sooner than 2029. As part of the collaboration agreement between Purdue Pharmaceutical Products L.P. and Transcept, Transcept is eligible to receive a $10 million milestone payment from Purdue in connection with the '131 patent being listed in the Orange Book. Pursuant to this agreement, Transcept is also eligible to receive up to an additional $70 million in milestone payments related to the achievement of certain U.S. net sales targets of Intermezzo, as well as a royalty on U.S. net sales of Intermezzo that ranges from the mid-teens to the mid-20% level.

[manny t]

TSPT,

Empire Asset Management Co. Initiates Coverage on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT)

Empire Asset Management Company, a FINRA member (143007), initiated coverage today on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT) with a buy rating and 12 month price target $12.50.

SOURCE Empire Asset Management Co.

Manny

[the_breeze]

I'm hoping the new sleep med will be a major part of their revenue reporting this Aug 9th.

[manny t]

Just saw this news.maybe the company will give information on how their new sleeping pill is doing.

Transcept Pharmaceuticals to Present at the JMP Securities Healthcare Conference

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the JMP Securities Healthcare Conference in New York on July 12, 2012 at 4:00 p.m. ET.

A live audio webcast and replay of this presentation may be accessed at http://wsw.com/webcast/jmp18/tspt/ and on the Transcept Investor webpage at www.transcept.com.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.

Contact:Transcept Pharmaceuticals, Inc.Greg MannSr. Director, Corporate Communications(510) [e-mail]



Manny

[manny t]

No news that I can see.

It must be getting some bottom fishing because there is a lot of speculation in Biotechs which is making them move higher.

I have a long way to go on this one,but am doing well on others.

Manny

[moldme1]

Any news driving today's pop?

[manny t]

TSPT,

Added more shares this time for 6.4 and 6.45 on news that in a 13G filing,Sabby management owns 7.74% of this company

They must have bought in the recent placement at 9 or just in the market at these low prices.

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8313064

Manny

[surf1944]

Transcept Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Press Release: Transcept Pharmaceuticals, Inc. – Fri, Jun 1, 2012 7:35 AM EDT
POINT RICHMOND, Calif., June 1, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the Jefferies 2012 Global Healthcare Conference in New York on June 7, 2012 at 1:30 p.m. ET.

A live audio webcast and replay of this presentation may be accessed at http://wsw.com/webcast/jeff68/tspt/ and on the Transcept Investor webpage at www.transcept.com.

[the_breeze]

Up 11%,,,kick the dog !!!

[manny t]

Congratulations.

Looks like your 2 dollar post was the time to buy.

Stock is at 7.02,up 10% for the day.

Manny

[the_breeze]

Thanks for the info Manny.. this stock could easily double if 3rd quarter Intermezzo sales look ok..IMHO.
ps..Stockdog is bashing my stock here because I was steppin on a Pump and Dump penney stock campaign of his with GRPS. Ignore him, he's my fault and my apologies for his 2 posts.

[manny t]

TSPT,

The company shows 59.21 million in cash in most recent quarter with 14.01 million outstanding shares.

Add 37.6 million in cash from recent share sale and add 4.5 million shares sold,you get 96.81 million dollars in cash,and 18.51 million shares.

96.81/18.51 gets you 5.23 dollars cash per share.

This is besides the potential revenue from their new sleep drug on the market,and the current 6.56 price is ridiculous.

Keep dreaming on 2 dollars.

Manny

[the_breeze]

You're funny, not too informed about this one, are we ?

[StockDog OTC]

Two dollars a share comming

Then much lower, no interest here at all, company will be delisted within 6 months

Too bad!!!

[StockDog OTC]

Beware if the company claims to be an industry leader (do you really think a penny stock can be a leader in anything except possibly scams?) or has made a breakthrough discovery. A company with legitimate breakthrough technology is unlikely to be promoting itself on the penny stock market and will most likely have funding available to it within a variety of partnerships with major companies. These same companies will not likely be interested in dealing with a penny stock company. Also, question the likelihood of a fairly new company being the leader in anything other than schemes

[the_breeze]

Manny..yeah I'm in and taking a severe beating...own 4200 shrs @10.52. Ouch ! IMHO, this Intermezzo should be a big hit, but 2nd and 3rd quarter results will tell. Did not want to stay in that long, it's not my style. Can't take a $15k hit either. I wanted to be long on this, but not 6-8 months..jeeez.

[manny t]

Anyone still in this stock?

This Market is really taking a drubbing lately,as am I.

I can't believe that Tang Capital took such a big stake at 9.,and this closed at 6.99.

I hope their new drug is selling well.

Manny

[manny t]

Cowen starts TSPT at outperform.

Manny

[manny t]

Transcept Pharmaceuticals to Report First Quarter 2012 Financial Results and Host Conference Call on May 14, 2012

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Monday, May 14, 2012, at 4:30 p.m. Eastern Time to discuss its first quarter 2012 financial results. The conference call will follow the release of the Transcept first quarter 2012 financial results after the close of market that day.

Conference Call Information Date: Monday, May 14, 2012 Time: 4:30 p.m. ET Dial-in (U.S.): 877-638-4558 Dial-in (International): 914-495-8537

A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call through July 31, 2012.

A telephone replay of the conference call will be available shortly after the conclusion of the call through May 19, 2012. The replay telephone number is 855-859-2056 (U.S.) or 404-537-3406 (International), replay passcode: 77576088.

About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.

Contact:Transcept Pharmaceuticals, Inc.Greg MannSr. Director, Corporate Communications(510) [e-mail]

SOURCE Transcept Pharmaceuticals, Inc.

[manny t]

Looks like Tang Capital likes this stock at 9 dollars.

In a filing Friday after hours,Tang capital has 9.5% stake in the company.

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8244464

It looks like Tang bought into the recent offering at 9 dollars,because they don't show up on major holders list.

http://finance.yahoo.com/q/mh?s=TSPT+Major+Holders

Manny

[the_breeze]

IMHO, with Intermezzo and the pipelined TO-2061 (OCD drug), I see no reason for this stock not to explode ! Go TSPT

[the_breeze]

Here's a little info on their pipeline drug..see website for more:

About TO-2061

Transcept is developing TO-2061, a low dose form of ondansetron, as an adjunctive therapy in patients with obsessive compulsive disorder (OCD) who have not adequately responded to approved first-line therapy. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families. Approximately 50 percent of patients do not respond adequately to standard first-line treatment with approved OCD medications, including the selective serotonin re-uptake inhibitors (SSRIs) and the tricyclic agent, clomipramine. There is no FDA approved augmentation therapy for these treatment resistant patients.

[the_breeze]

Good point Raj..I'm going to wait a few days and then maybe average down...this pps has to settle before I make a move.
they have another drug in the pipeline too as stated on their website...looks promising, a compulsive disorder helper.

[kris_kade]

This is why it's so important to watch for how may quarters company has cash. cash flow analysis is critical to call out the spike before secondary hits. Nevertheless, no easy way to beat the 'distant cousins'...

I see this an excellent opportunity to load up and/or average down..the drug will be a blockbuster.

[manny t]

The people who are in on the Private Placement,are the same people who work the stock price up so they can Short it.

A nice way to make a killing(living).

Manny

[healey]

Good point, I wonder how early people knew..if they knew at 12$ that was a hefty return with almost nil risks.

[mlkrborn]

Stox sale @ $9
Transcept Pharma prices public offering of 4.5mln shares of common stock at $9.00 per share (TSPT) 11.00 :

[manny t]

Imagine the money these crooks who are in the know of the private palcement make.

They can have their "friends" Short into the price rise,and know that it is guaranteed money,as the price drops into the private placement.

Crooks.

Mann

[the_breeze]

I'm in deep...3200 shrs @11.06 cost per share...ouch. I day traded for several days a little while back and made some bucks, but now I'm taking a beatin' !

[manny t]

TSPT,

I bought back into the stock.I was out of it for the last run.

[the_breeze]

Good point..I'm long on this stock. This new drug will probably do very well since it's the only one of it's kind. IMO

[zambono]

not at all, it was great to see the shorters couldn't do much more damage and then they announce this offering. I'm long and still believe that Intermezzo will be selling well

[the_breeze]

picked up some shares in pre-market @ 9.65..it's all gambling anyway.
GO TSTP !!!

[the_breeze]

sure as hell isn't helping the pps. crap.

[zambono]

That's what it seems, to what purpose we don't know or when it will happen. Some ate suggesting they might need cash now to increase workforce. We shall see

[the_breeze]

from the news after bell yesterday I guess there will be dilution going on or what ?